ES2145694A1 - Metodo de aislamiento de un agregado celular y agregado celular resultante. - Google Patents

Metodo de aislamiento de un agregado celular y agregado celular resultante.

Info

Publication number
ES2145694A1
ES2145694A1 ES009800313A ES9800313A ES2145694A1 ES 2145694 A1 ES2145694 A1 ES 2145694A1 ES 009800313 A ES009800313 A ES 009800313A ES 9800313 A ES9800313 A ES 9800313A ES 2145694 A1 ES2145694 A1 ES 2145694A1
Authority
ES
Spain
Prior art keywords
neurodegeneration
treatment
aggregate
cerebrovascular disorder
neuromodulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009800313A
Other languages
English (en)
Other versions
ES2145694B1 (es
Inventor
Butron De Mugica Jose Armengol
Espejo Emilio Fernandez
Laseca Rafael Jesus Montoro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Sevilla
Original Assignee
Universidad de Sevilla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Sevilla filed Critical Universidad de Sevilla
Priority to ES009800313A priority Critical patent/ES2145694B1/es
Priority to PCT/IB1999/000246 priority patent/WO1999040924A2/en
Publication of ES2145694A1 publication Critical patent/ES2145694A1/es
Application granted granted Critical
Publication of ES2145694B1 publication Critical patent/ES2145694B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Método de aislamiento de un agregado celular y agregado celular resultante.La invención se refiere al uso de células o agregados de células sensibles a hipoxia, por ejemplo del cuerpo carotídeo, sometidos o no a un tratamiento enzimático suave, que no llegue a disgregar el tejido en células aisladas. De este modo, el tejido se trata enzimáticamente pero no se dispersa mecánicamente. Las células segregan neurotransmisores, neuromoduladores o enzimas y podrían ser de utilidad para el tratamiento de enfermedades neurodegenerativas originadas por el déficit de una molécula, que sería el producto de secreción de las células trasplantadas. Es de destacar que las célulassegregan en respuesta a la hipoxia y, en un cerebro huésped, las células trasplantadas se van a encontrar en una situación de baja presión parcial de oxígeno, estimulante de la secreción.
ES009800313A 1998-02-11 1998-02-11 Metodo de aislamiento de un agregado celular y agregado celular resultante. Expired - Fee Related ES2145694B1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES009800313A ES2145694B1 (es) 1998-02-11 1998-02-11 Metodo de aislamiento de un agregado celular y agregado celular resultante.
PCT/IB1999/000246 WO1999040924A2 (en) 1998-02-11 1999-02-11 Treatment of neurodegeneration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009800313A ES2145694B1 (es) 1998-02-11 1998-02-11 Metodo de aislamiento de un agregado celular y agregado celular resultante.

Publications (2)

Publication Number Publication Date
ES2145694A1 true ES2145694A1 (es) 2000-07-01
ES2145694B1 ES2145694B1 (es) 2001-02-01

Family

ID=8302792

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009800313A Expired - Fee Related ES2145694B1 (es) 1998-02-11 1998-02-11 Metodo de aislamiento de un agregado celular y agregado celular resultante.

Country Status (2)

Country Link
ES (1) ES2145694B1 (es)
WO (1) WO1999040924A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2578165A1 (en) * 2011-10-08 2013-04-10 Martin Ivanov Denev Method for stopping aging of the body by replacing of the old biocathode centers by young biocathode centers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ESPEJO, E.F. et al.: "Cellular and functional recovery of parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates", febrero 1998, Neuron, Vol. 20 (2), paginas 197-206 *
GUOYING, B. et al.: "Comparison of adrenal medullary, carotid body and PC12 cell grafts in 6-OHDA lesioned rats", 1988, Brain Res. Bull., Vol. 20, paginas 399-406 *
HANSEN, J.T. et al.: "Paraneural grafts in unilateral 6-hydroxydopamine-lesioned rats: morphological aspects of adrenal chromaffin and carotid body glomus cell implants", 1988, Progress in Brain Res., Vol. 78, paginas 507-511, *
MOKRY, J.: "Parkinson's disease: contemporary state and perspectives", 1994, Sbornik Vedeckych Praci LF UK Hradec KralovÉ, Vol 37 (1), paginas 5-12 *

Also Published As

Publication number Publication date
ES2145694B1 (es) 2001-02-01
WO1999040924A2 (en) 1999-08-19
WO1999040924A3 (en) 1999-11-25

Similar Documents

Publication Publication Date Title
AU4832199A (en) Dietary supplement for supporting cerebrovascular tone
WO2000047219A3 (en) Methods and reagents for treating glucose metabolic disorders
HK1045311A1 (en) Triazole compounds with dopamine-d3-receptor affinity
MY121486A (en) Anticonvulsant derivatives useful in treating cluster headaches
HK1045852A1 (en) Polyurethane solutions containing alkoxysilane structural units
MY121294A (en) Novel hexanoic acid derivatives.
PL338339A1 (en) Novel derivatives of tetrazole
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
AU4221399A (en) Human cd45+ and/or fibroblast + mesenchymal stem cells
BG103664A (en) Pharmaceutical forms containing ammoxycillin and clavulanate
MXPA01007710A (es) Agente de secado por congelacion que contiene paramilon, su produccion y uso.
MY131298A (en) 5-heteroyl indole derivatives
HK1031120A1 (en) Novel exendin agonist compounds
GR3037074T3 (en) Protein kinase c inhibitors
MXPA01008465A (es) Complejos de anticuerpo de quimiocina biotinilada.
TR199800415T1 (en) Farmas�tik form�lasyon.
EP1061806A4 (en) PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES
AU6886996A (en) Building plaything primarily for creating rolling tracks
EP0671768A3 (en) Improvements in or regarding electrodes for LSI.
CA2317954A1 (fr) Dispositif d'enrobage pour granules a absorber par voie orale
ES2145694A1 (es) Metodo de aislamiento de un agregado celular y agregado celular resultante.
ZA965865B (en) Zeolites and processes for their manufacture
DE69625910T2 (de) Penamsulfone als beta-laktamase inhibitoren
HK1040906A1 (en) Null igf for the treatment of cancer.
HUT47299A (en) Process for producing pharmaceutical influencing cerebral metabolism and neuronal transmission

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000701

Kind code of ref document: A1

Effective date: 20000701

FD2A Announcement of lapse in spain

Effective date: 20180525